Editorial: Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 5, 2009, Pages 509-512

  Ammann, Arthur J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTIFICIAL MILK; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; EDITORIAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL TREATMENT; MONOTHERAPY; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PRIORITY JOURNAL; PROPHYLAXIS; REBOUND; SHORT COURSE THERAPY; SINGLE DRUG DOSE; VERTICAL TRANSMISSION; VIRUS MUTATION; DISEASE TRANSMISSION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; INFANT; MUTATION; NEWBORN; NOTE; PREGNANCY; PREGNANCY COMPLICATION; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MUTATION; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ZIDOVUDINE;

EID: 68449085048     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181aa8a3d     Document Type: Editorial

References (56)

1. Lehman DA, Chung MH, Mabuka JM, et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr. 2009;51:522-529.
2. Mofenson L. Overview of periantal intervention trials table. 2008. Available at: http://www.womenchildrenhiv.org/wchiv?page=wx-resource&root= typ&cat=02&subcat=prov&rid=20-7854. Accessed March 10, 2009.
3. Chigwedere P, Seage GR, Lee TH, et al. Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials. AIDS Res Hum Retroviruses. 2008;24:827-837.
4. Sripipatana T, Spensley A, Miller A, et al. Site-specific interventions to improve prevention of mother-to-child transmission of human immunodeficiency virus programs in less developed settings. Am J Obstet Gynecol. 2007;197(3 Suppl):S107-S112.
5. Volmink J, Siegfried NL, van der Merwe L, et al. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007(1):CD003510.
6. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
7. Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med. 1997;337:853-856.
8. Bonkovsky FO. Ethical issues in perinatal HIV Clin Perinatal. 1994;21:15-28.
9. Rouse DJ, Owen J, Goldenberg RL, et al. Zidovudine for the prevention of vertical HIV transmission: a decision analytic approach. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:401-407.
10. Brocklehurst P, Volmink J. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2002(2):CD003510.
11. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
12. Stringer JS, Chi BH. Extended nevirapine prophylaxis to prevent HIV transmission. Lancet. 2008;372:267-269.
13. Welty TK, Bulterys M, Welty ER, et al. Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon. J Acquir Immune Defic Syndr. 2005;40:486-493.
14. Baldanti F, Paolucci S, Maga G, et al. Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine. AIDS. 2003;17:1568-1570.
15. Church JD, Omer SB, Guay LA, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis. 2008;198:1075-1082.
16. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med. 2000;343:982-991.
17. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February 23, 2009:1-139. Available at: http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf. Washington, DC: DHHS; 2008. Accessed March 10, 2009.
18. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. 2008. Available at: http://www.who.int/hiv/pub/guidelines/pmtct/en/. Accessed March 10, 2009.
19. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
20. De Cock KM, Gilks CF, Lo YR, et al. Can antiretroviral therapy eliminate HIV transmission? Lancet. 2009;373:7-9.
21. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
22. WHO. Post-exposure prophylaxis to prevent HIV infection. 2007. Available at: http://www.who.int/hiv/pub/prophylaxis/pep-guidelines/en/index.html. Accessed March 9, 2009.
23. CDC releases detailed guidelines for PEP use. Agency focuses on nonoccupational exposure. AIDS Alert. 2005;20:42-44.
24. WHO. Antiretroviral therapy for HIV infection in adults and adolescents. 2008. http://www.who.int/hiv/pub/guidelines/adult/en/. Accessd March 10, 2009.
25. WHO. Antiretroviral therapy of HIV infection in infants and children: towards universal access. 2006. Available at: http://www.who.int/hiv/pub/ guidelines/art/en/index.html. Accessed May 26, 2009.
26. Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV MMWR Recomm Rep. 2002;51(RR-7):1-55.
27. Fox Z, Phillips A, Cohen C, et al. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 2008;22:2279-2289.
28. Eron JJ. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. J Infect Dis. 2008;197(Suppl 3):S261-S271.
29. Benson CA, Vaida F, Havlir DV, et al. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis. 2006;194:1309-1318.
30. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. lancet. 2006;367:1981-1989.
31. Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007;8:96-104.
32. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908.
33. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science. 2003;301:1535-1537.
34. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605-1612.
35. Corbett EL, Marston B, Churchyard GJ, et al. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. lancet. 2006;367:926-937.
36. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283:1175-1182.
37. Janssen RS, Holtgrave DR, Valdiserri RO, et al. The serostatus approach to fighting the HIV epidemic: prevention strategies for infected individuals. Am J Public Health. 2001;91:1019-1024.
38. Perez H, Vignoles M, Laufer N, et al. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen. Antivir Ther. 2008;13:135-139.
39. Gray GE, Saloojee H. Breast-feeding, antiretroviral prophylaxis, and HIV N Engl J Med. 2008;359:189-191.
40. Chi BH, Chintu N, Cantrell RA, et al. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission. J Acquir Immune Defic Syndr. 2008;48:220-223.
41. Coffie PA, Ekouevi DK, Chaix ML, et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis. 2008;46:611-621.
42. Tonwe-Gold B, Ekouevi DK, Viho I, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med. 2007;4(8):e257.
43. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr. 2008;48:315-323.
44. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008;359:119-129.
45. Leroy V, Sakarovitch C, Cortina-Borja M, et al. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HFV in Africa? AIDS. 2005;19:1865-1875.
46. Phanuphak P. Ethical issues in studies in Thailand of the vertical transmission of HIV N Engl J Med. 1998;338:834-835.
47. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999;353:773-780.
48. Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA. 2004;292:202-209.
49. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409-1414.
50. Violari A, Cotton M, Gibb D. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) study. Abstract WESS103. Presented at: Fourth International AIDS Society Conference on HIV Treatment and Pathogenesis; July 22-27, 2007; Sydney, Australia.
51. Welch SB, Gibb D. When should children with HIV infection be started on antiretroviral therapy? PLoS Med. 2008;5(3):e73.
52. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005;19:309-318.
53. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951-1957.
54. Faye A, Le Chenadec J, Dollfus C, et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis. 2004;39:1692-1698.
55. Suksomboon N, Poolsup N, Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther. 2007;32:293-311.
56. WMA. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Available at: http://www.wma.net/e/policy/b3.htm. 2004. Accessed March 9, 2009.